.2 mg/kg of body weight, respectively). Against four highly Ery-resistant (Ery r ) strains for which ABT MICs were low, ABT showed much greater activity (PD 50 , 6.3 to 32.5 mg/kg) than ERY (PD 50 , >200 mg/kg) but was not protective for strains for which ABT MICs were high. In conclusion, ABT-773 showed in vivo efficacy and considerably greater activity than ERY in a mouse peritonitis model.
Enterococci are important causes of nosocomial infections, including infective endocarditis, urinary tract infections, and bacteremia (7, 14) , and are problematic because of increasing antibiotic resistance. Although two agents (quinupristin-dalfopristin and linezolid) have been approved for use against vancomycin-resistant (Van r ) enterococci since 1999, emergence of resistance to these agents among vancomycin-resistant enterococci and/or adverse events have continued the need for new antibiotics (5, 6) . ABT-773 (cethromycin [ABT] ) is a new semisynthetic ketolide that differs from the natural macrolide erythromycin (ERY), with an 11,12-position cyclic carbamate group in addition to the 3-keto group. ABT has a broad spectrum of activity against some gram-positive, gram-negative, and intracellular bacteria (1, 3, 4, 17, 18) , but there is no published information regarding in vivo activity against enterococci. In the present study, we evaluated the activity of ABT against Enterococcus faecalis and Enterococcus faecium strains with various susceptibilities to ERY in a mouse peritonitis model and found that the in vivo efficacy of ABT was considerably greater than that of ERY.
This work was presented in part at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (S. R. Pai, K. V. Singh, and B. E. Murray, Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. B-1652, 2001).
Six E. faecalis isolates were selected for the present study based on their varied antibiotic susceptibility profiles (Table 1) . E. faecalis OG1RF (ATCC 47077) is a commonly used strain that is plasmid free (9) . E. faecalis TX0921 (HH22) is a ␤-lactamase-producing strain with high-level resistance to gentamicin (Gen r ) (8 (9, 10) by agar dilution with Mueller-Hinton agar II (Becton Dickinson and Company, Cockeysville, Md.) and using E. faecalis ATCC 29212 as a control strain. Enterococci were considered susceptible (Ery s ) when the MIC of ERY was Յ0.5 g/ml, intermediate when the MIC was between 1 and 4 g/ml, and resistant when the MIC was Ն8 g/ml (10, 11).
Female, 4-to 6-week-old, outbred ICR mice (Harlan Sprague Dawley, Houston, Tex.) with a mean weight of 25 g were used in the study. The 50% lethal dose (LD 50 ) of enterococci for mice was determined as described earlier (15), with a 12.5% concentration of sterile rat fecal extract (SRFE). SRFE was prepared using crushed, dried rat feces by mixing with 2 volumes of 0.9% (wt/vol) saline and autoclaving at 121°C and 15 lb of pressure for 15 min. The autoclaved sample was centrifuged at ϳ1,543 ϫ g at a temperature of 4°C, and the supernatant (100% SRFE) was reautoclaved under the conditions described above. Table 1 shows the LD 50 s observed. To determine the 50% protective doses (PD 50 s), both ABT and ERY were administered by subcutaneous (s.c.) injection immediately following intraperitoneal inoculation of 10 ϫ the LD 50 of enterococci in SRFE, except in the initial stages, in which ABT was also administered orally (p.o.) by gavage. When two doses were used, they were administered at 0 and 4 h after infection. The dose ranges studied were between 3.12 and 100 mg/kg of body weight. The PD 50 s of ABT and ERY were determined by the method of Reed and Muench (12) . Six mice/dose/drug were used to generate LD 50 and PD 50 values and dose response curves. In both the LD 50 and PD 50 experiments, mouse spleen homogenates were used to recover and confirm the identity of the lethal organism either by phenotypic characteristics or by using pulsed-field gel electrophoresis.
MICs of the antibiotics are shown in Table 1 along with the LD 50 and PD 50 values, and dose-response curves are shown in Fig. 1 . Strains with erm(B) that were highly resistant to ABT and ERY were classified as cMLS B , whereas those highly resistant to ERY only were considered to be iMLS B .
For i )-infected mice showed no protection even at the highest dose of ERY (200 mg/kg). For this reason, the remainder of the study was performed using injections.
For OG1RF mice inoculated by the s.c. route, ABT displayed a PD 50 value 7.7 times lower than the PD 50 value found for ERY (ABT PD 50 , 4.1 mg/kg; ERY PD 50 , 31.5 mg/kg). For E. faecalis TX0921-infected mice, ABT displayed a PD 50 value (0.5 mg/kg) that was 31 times lower than the PD 50 value found for ERY (PD 50 , 15.7 mg/kg). ABT displayed MICs of 0.062 and 0.031 g/ml for OG1RF and TX0921, respectively, and ERY displayed MICs of 0.5 g/ml for both strains.
Both ABT and ERY displayed high PD 50 values for mice infected with the highly ERY-and ABT-resistant E. faecalis strains TX0052 and V583 and E. faecium TX0016 (DO). The two-dose regimen for infected mice, consisting of one dose of 50 mg of ABT/kg of body weight at time zero and a second dose after a 4-h interval, presented better protection and survival than the 100-mg/kg regimen, suggesting that the higher level of mortality at 100 mg/kg was due in part to drug toxicity.
Unlike the nonprotective effect observed against strains highly resistant to ABT and ERY, an in vivo protective effect of ABT was seen against E. faecalis strains highly resistant to ERY but for which ABT MICs were low, with an ABT PD 50 of 32.5 mg/kg for E. faecalis TX0860 (ERY MIC, Ͼ512 g/ml; ABT MIC, 0.062 g/ml)-infected mice and an ABT PD 50 value of 6.25 mg/kg for E. faecalis TX0641 (ERY MIC, Ͼ512 g/ml; ABT MIC, 0.031 g/ml)-infected mice. Protective effects were also seen with ABT for E. faecium TX2597 (ABT MIC, 0.016 g/ml; ERY MIC, 16 g/ml)-infected mice and E. faecium TX4051 (ABT MIC, 0.031 g/ml; ERY MIC, 16 g/ml)-infected mice, with ABT PD 50 s of 16.2 and 9.1 mg/kg, respectively.
It is of interest that while the ABT MICs were similar for the more ABT-sensitive (MICs, Յ0.062 g/ml) E. faecalis and E. faecium strains, the PD 50 s were lower against three of the four E. faecalis strains than those against the four E. faecium strains; the reason for this in vivo-in vitro difference is not known. Two of these E. faecalis strains were Ery s , and the other two were erm (B) ϩ with the iMLS B phenotype. None of the E. faecium strains for which the ABT MICs were very low were erm (B) ϩ , but for each strain, the ERY MIC was 2 to 16 g/ml, a result perhaps related in part to the presence of msrC (16) . The in vivo activity (both intra-and interspecies) of ABT against ERY-susceptible and -intermediate resistance enterococci was also observed to be similar to that of telithromycin (HMR 3647) in the mouse peritonitis model, which also showed some efficacy when two doses were given s.c., indicating that it might be possible to achieve an effect even against more resistant organisms (15).
In conclusion, ABT showed in vivo efficacy against ERYsusceptible and ERY-intermediate enterococci and against some highly ERY-resistant enterococci that were inhibited by low concentrations of ABT. As with in vitro results, ABT was FIG. 1. Dose-response curves. (A) Drug-only (no bacteria) control animals showed 100% survival, and animals in the infection control (no antibiotic) group that were infected with E. faecalis strain OG1RF showed 0% survival. All of the mice received s.c. therapy with ABT or ERY for peritonitis caused by E. faecalis strain OG1RF. (B) Drug-only (no bacteria) control animals showed 100% survival, and animals in the infection control (no antibiotic) group that were infected with E. faecium strain TX2465 showed 0% survival. All the mice received s.c. therapy with ABT or ERY for peritonitis caused by E. faecium strain TX2465.
